Product Certification&
Enterprise Certification
Country: China (Mainland)
Business Type:Lab/Research institutions
Tel: +86-173-20513646
Tel: +86 17320513646
Mobile: 17320513646
Tel: +86-173-20513646
Fax:
Province/state: Hu Bei
City: Wuhan
Street: Company address: Room 005, 15th Floor, Building D2, Phase III, Software New Town, No. 8 Huacheng Avenue, East Lake High-tech Development Zone, Wuhan, Hubei Province, China
MaxCard:
CAS NO.887001-08-3
1(0.1-10)Metric Ton
1. We integrate R&D, production and sales. A 5,000-square-meter high-standard bio-intelligent manufacturing base can ensure high quality and fast delivery of products. The professional sales team ensures that you don't need to worry about pre-sales and after-sales.
2. We focus on pharmaceutical standards, pharmaceutical intermediates, pharmaceutical impurity controls, peptide customization, our own laboratory, and undertake customized synthesis projects.
3. We offer products from gram grade to g grade, in addition, some product specifications and packaging can be customized.
4. We have been deeply engaged in the pharmaceutical field for ten years and have rich experience. At present, customers are all over the world, and have been highly recognized and trusted by customers.
5. We can provide a variety of safe ways to transport goods for you to choose.
Rizatriptan EP Impurity A(Dihydrochloride)
Product Information
Product Code:R047002A
English Name:Rizatriptan EP Impurity A(Dihydrochloride)
English Alias:2-(5-((1H-1,2,4-triazol-1-yl)methyl)-2-((3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)methyl)-1H-indol-3-yl)-N,N-dimethylethanamine dihydrochloride
CAS No.:[Not Available]
Molecular Formula:CHN·2HCl
Molecular Weight:542.54
Advantages
High-Purity Reference Standard:Confirmed by HPLC (≥99.0%), NMR (1H, 13C), HRMS, and elemental analysis, compliant with EP (European Pharmacopoeia) impurity standards for Rizatriptan quality control.
Stability Assurance:Stable for 36 months at -20℃ under light-protected, sealed storage; degradation rate <0.3% in aqueous solution (pH 4-6) within 6 months.
Applications
Quality Control Testing:Used for HPLC and LC-MS detection of EP Impurity A in Rizatriptan API and formulations, controlling content to meet EP standards (≤0.1%).
Process Optimization Research:Monitors impurity formation during Rizatriptan synthesis, reducing generation by >50% by adjusting condensation temperature (e.g., 80-90℃) and reaction time.
Method Validation:Serves as an EP standard for developing impurity detection methods, verifying HPLC resolution (≥2.5) and LOD (0.01 ng/mL).
Background Description
Rizatriptan, a 5-HT receptor agonist, is used for migraine treatment. Impurity A, specified by EP, may originate from alkylation side reactions of the indole ring or triazole group introduction during synthesis. Its polyamino and indole ring system may affect drug stability and efficacy. With stricter EMA enforcement of EP standards, studying such officially designated impurities is crucial for drug registration and manufacturing.
Research Status
Detection Technology:UPLC-MS/MS with C18 column (1.7μm) and 0.1% formic acid-acetonitrile gradient elution achieves separation within 4 minutes, with LOD of 0.003 ng/mL for EP-compliant trace analysis.
Formation Mechanism:Formed by reaction of 3-(2-(dimethylamino)ethyl)-5-methylindole with 1,2,4-triazolylmethyl halide under alkaline conditions (e.g., potassium carbonate catalysis); optimizing catalyst dosage and solvent polarity (e.g., DMF-water system) inhibits side reactions.
Safety Evaluation:In vitro cytotoxicity shows IC of 186.5 μM against SH-SY5Y cells (Rizatriptan IC=12.3 μM), with low toxicity but requiring ≤0.1% limit. Long-term stability testing is ongoing to monitor degradation under different pH conditions.